International Journal of Clinical Research

Objective This article will delve into the clinical effects of applying dapagliptin to patients with coronary heart disease and heart failure, in order to improve their clinical symptoms and quality of life. Methods A total of 68 patients with coronary heart disease and heart failure were selected from our hospital from January 2021 to June 2022. The patients were informed to participate in the conventional group (34 people) and the treatment group (34 people). The conventional group was given routine treatment, and the treatment group was treated with dapagliptin on this basis. The clinical treatment effect of the two groups of patients was compared. Results There was no significant difference in cardiac function levels among all patients before treatment (p>0.05). After treatment, all cardiac function indicators in the treatment group were better than those in the conventional group (P<0.05); There was no significant difference in inflammatory indicators among patients before treatment (P>0.05), and the improvement effect of inflammatory indicators in the treatment group was better than that in the conventional group after treatment (P<0.05); There is a significant difference in the treatment effect between the two groups of patients (P<0.05), and the improvement rate is compared to the treatment group: 94.12% in the conventional group: 73.53%; The treatment groups treatment satisfaction (97.06%) was much better than the conventional groups (76.47%, P<0.05). Conclusion In clinical treatment of patients with coronary heart disease combined with heart failure, the use of daggliflozin on the basis of conventional treatment has ideal clinical treatment effects, which can effectively improve clinical symptoms, enhance heart function, and reduce inflammatory indicators. Patients have high satisfaction with treatment, which is conducive to improving clinical treatment effectiveness and service quality.

Daggliflozin; Coronary heart disease; Heart failure; Clinical effects